A trial fibrillation (AF) is associated with a 5-fold risk of stroke, a 3-fold incidence of congestive heart failure, and higher mortality. 1 Despite antiarrhythmic drug therapy, reported recurrence rates of AF are 50% to 60% during a mean follow-up of 1 to 2 years. [2] [3] [4] [5] In symptomatic AF patients who have rapid ventricular rates refractory to drug therapy, atrioventricular nodal radiofrequency ablation (AVNA) with permanent ventricular pacing (PVP) is an approach that is effective to control the ventricular rate. 2,6-9 Although it does not eliminate AF and may be perceived as an old-style procedure, the procedure generally alleviates symptoms and improves quality of life, exercise tolerance, and left ventricular function. [10] [11] [12] [13] [14] [15] It is especially valuable when rate cannot be controlled with drugs, AF cannot be prevented by antiarrhythmic therapy or is associated with intolerable side effects, or AF ablation is not indicated, has failed, or is rejected. 2 AVNA should also be considered for patients with permanent AF and an indication for cardiac resynchronization therapy (CRT). 16 Despite its potential utility, long-term outcomes after AVNA have not been assessed. Short-term follow-up may not capture the long-term risks of an irreversible procedure and need for pacing. Some studies found that AVNA with PVP may induce a deterioration in LV function. 17, 18 Here, we evaluate the relatively long-term outcomes of AF patients after AVNA.
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department at the University Hospital of Tours with a diagnosis of AF from January 1, 2000 , to December 31, 2014, were systematically identified from hospital discharge records. Extensive information on date of admission, discharge, diagnosis, clinical presentation, AF pattern (paroxysmal, persistent, or permanent) comorbidities, performed procedures, medication, subsequent hospitalization, adverse events, and in-hospital death were collected. All-cause mortality was collected for all patients until December 31, 2014. AVNA was performed by standard techniques. 20 Complete heart block was achieved by percutaneous catheter radiofrequency ablation with venous femoral access in all the cases. The permanent pacemaker was typically implanted 2 days before AVNA and programmed to VVI 40 during ablation to ascertain presence of heart block and thereafter programmed to VVIR at 75 beats per minute for at least 3 months.
After AVNA, patients were followed by the referring cardiologist at least every 12 months, and data were censored at the time of last known follow-up. During follow-up, all-cause mortality was recorded in the hospital coding system and information collected until December 31, 2014 . The institution includes a total of 4 hospitals covering all specialties and is the only public institution in an area of around 4000 km 2 , serving ≈400 000 inhabitants. Deaths were also identified using a search tool from a dedicated website for the Région Center, http://nrco.lanouvellerepublique.fr/dossiers/ necro/index.php.
This type of study was approved by the institutional review board of the Pole Coeur Thorax Vaisseaux from the Trousseau University Hospital on December 7, 2010, and registered as a clinical audit. Ethical review was, therefore, not required. Patient consent was not sought. Written informed consent was, however, obtained for all patients undergoing AVNA and device implantation. The study was conducted retrospectively, patients were not involved in its conduct, and there was no impact on their care.
Assembly of a Balanced Study Cohort
To attenuate between-group imbalances on baseline patient characteristics, we used propensity scores to assemble a cohort with 1:1 matching in which patients treated or not treated with AVNA would be well balanced on all key measured baseline confounders. We estimated the propensity score for being treated with AVNA for each participant, using a multivariable logistic regression model in which AVNA was the dependent variable, and the variables presented in Table 1 were included as covariates. Using a matching protocol, we then assembled a cohort of pairs of AF patients treated and not treated with AVNA. The criterion for matching was the single propensity score, obtained from the logistic regression model.
Statistical Analysis
Patient characteristics are reported as percentages and mean±standard deviation (SD). Comparisons between groups were made using χ 2 tests for comparing categorical variables and the Student's t test or nonparametric Kruskal-Wallis test where appropriate for continuous variables. A proportional hazards regression model with stepwise analysis was used to calculate the hazard ratio and 95% confidence interval (CI) of predictive factors for the incidence of death in the nonmatched cohort. The proportional hazard assumption was checked by plotting the log-log Kaplan-Meier curves. Model adequacy for propensity score was verified using Hosmer-Lemeshow test. In the matched cohort, because the AVNA and no AVNA groups may no longer be independent after the matching, the analysis on outcomes took into account that the 2 groups may be dependent because of matching. 21 We calculated relative differences of events using a McNemar's test for correlated proportions and odds ratios using conditional logistic regression. A P value <0.05 was considered statistically significant. Statistical analysis was performed with the Statview 5.0 software (SAS Institute Inc, Cary, NC) and the Stata version 13 software (StataCorp LP, College Station, TX).
Results
A total of 9122 consecutive patients with AF were included. There were 453 patients (5%) with AF who underwent AVNA. Among them, 265 (58%) had permanent AF, 117 (26%) received an implantable cardioverter defibrillator, and 167 (37%) had CRT, among whom 100 (60%) had CRT-implantable cardioverter defibrillator. Patient characteristics are listed in Table in the Data Supplement. In patients with AVNA, the number of drugs previously used for rhythm control was 1.7±0.6, the number of drugs previously used for rate control was 1.3±0.8, and 5 patients (1.1%) previously had radiofrequency ablation for AF in the left atrium with circumferential pulmonary vein isolation, left atrial roof and mitral isthmus linear ablation, and complex fractionated atrial electrogram ablation. Patients with AVNA were older than other AF patients and more likely to have heart failure, hypertension, coronary artery disease, valvular heart disease, renal failure, permanent AF, lower left ventricular ejection fraction, CRT, implantable cardioverter defibrillator, and higher CHA 2 Characteristics of matched AF patients treated with AVNA or no AVNA are listed in Table 1 . Compared with prematch patients, those in the matched cohort showed markedly improved balance across the baseline characteristics ( Figure 1 ). Postmatch differences for all measured covariates suggested substantial balance across the groups. The propensity model yielded a concordance index (C index) of 0.87 (95%
WHAT IS KNOWN
• Atrioventricular nodal ablation with permanent ventricular pacing can be used to control ventricular rate in patients with atrial fibrillation and, generally, alleviates symptoms and improves quality of life, exercise tolerance, and left ventricular function.
• Despite its potential utility, long-term outcomes after atrioventricular nodal ablation have not been assessed and are uncertain in light of irreversible pacemaker dependence.
WHAT THE STUDY ADDS
• In symptomatic atrial fibrillation patients with multiple comorbidities, atrioventricular nodal ablation with permanent ventricular pacing for rate control appears safe and may be associated with lower mortality and lower cardiovascular mortality during follow-up.
• Atrioventricular nodal ablation with permanent ventricular pacing in these patients might also be associated with a lower risk of stroke and thromboembolic events.
CI 0.86-0.88; P=0.0001), indicating a good ability to differentiate between patients treated with AVNA use or no AVNA use.
Over 2.31±3.15 years of follow-up (median 1.22, quartiles 0.36-2.86) after AVNA, 36 patients (8%) had conduction recurrence necessitating a second ablation procedure, 8 patients (2%) had an upgrade to CRT, 4 patients (1%) needed repositioning of the right ventricular lead, 1 patient (0.2%) had syncope related to ventricular tachycardia with subsequent heart transplantation, and 45 patients (10%) had battery replacement. During follow-up in the whole population, 1184/9122 patients (13%) died. In the propensity-matched cohort, duration of follow-up was similar in patients with AVNA (2.41±3.23 years, median 1.23, quartiles 0.33-3.12) and in patients with no AVNA (2.41±2.76, median 1.30, quartiles range 0.18-3.62; P=0.98), and 100 deaths (6.6%/y) were recorded. We had information for the mode of death in 86% of patients, which was cardiovascular in 67% of the patients (related to heart failure in 38%, sudden death in 5%, and other cardiovascular reason in 24%) and noncardiovascular in 33%. Using the McNemar test for correlated proportions, there was a lower rate of events for all-cause death in AF patients with AVNA (relative difference 0.41, 95% CI 0.36-0.46; P<0.0001) for cardiovascular death (relative difference 0.44, 95% CI 0.40-0.49; P<0.0001) and for stroke/ TE (relative difference 0.45, 95% CI 0.40-0.50; P<0.0001). AVNA in patients with AF after propensity matching was associated with a lower risk of mortality (odds ratios 0.47, 95% CI 0.29-0.77; P=0.003; Figure 2 ) and a lower risk of cardiovascular mortality (odds ratios 0.41, 95% CI 0.23-0.73; P=0.003; Figure 3 ). In addition, AVNA in the propensity-matched cohort was associated with nonsignificant lower risk of stroke and thromboembolic events (odds ratios 0.61, 95% CI 0.36-1.06; P=0.08; Figure 4 ). We also performed a multivariate stepwise analysis using Cox proportional-hazards model of the whole population of AF patients with adjustment on potential confounders listed in Table 1 . Older age, diabetes mellitus, smoking, lack of dyslipidemia and hypertension, heart failure, history of acute coronary syndrome, severe valve disease, permanent AF, dialysis, history of cancer, HAS-BLED score use of diuretic, and lack of beta blockers use were significantly associated with a higher risk of mortality ( Table 2 ).
Discussion
To date, mortality after AVNA and pacemaker treatment of chronic AF has not been evaluated systematically against a control group of medically treated AF patients during longterm follow-up. We present the first analysis with propensity score matching in a relatively large series of AF patients with AVNA. This large registry-based cohort study with systematic identification of consecutive AF patients showed that among patients with AF, (1) those with AVNA had a higher risk of (3) AVNA, when considered as a last resort therapy for these sick patients with multiple comorbidities, was associated with a lower risk of all-cause and cardiovascular mortality after adjustment for confounders or propensity matching.
Mortality post AVNA was similar to that described by Gasparini (3%/y after a mean follow-up of 34 months), 22 although it seemed to be lower beyond the fifth year after the procedure in our analysis. AVNA with PVP can improve symptoms and quality of life in selected AF patients with refractory symptoms. Benefits include reduction in heart failure, perhaps related to better rate control and improved diastolic filling. 23 We show in a large well-matched cohort of AF patients that AVNA with PVP performed in sick AF patients is safe over a relatively long-term and may even be associated with a trend toward a decreased mortality. In the propensitymatched cohort, AVNA was indeed associated with a significantly lower risk of cardiovascular mortality and a lower rate of stroke and thromboembolic events. Our results may confirm the fairly low incidence of thromboembolic events that has previously been reported after AVNA and pacing for drug refractory rapid AF. 24 Previous studies have evaluated benefits associated with AVNA in shorter follow-up. Brignole et al found in a multicenter, controlled, randomized study with 12-month followup that in 66 patients with heart failure and permanent AF, treatment with AVNA and VVIR pacemaker implantation was superior to drug therapy to control symptoms. There was no increased risk of death, especially sudden death, early or on the midterm. 25 Similar results were obtained in 43 patients with paroxysmal AF and assessment of AVNA with DDDR mode-switching pacemaker versus pharmacological treatment. 26 Ozcan et al, in longer-term follow-up, observed that survival among patients undergoing ablation was similar to that expected in a general population. 27 Safety of AVNA to control the ventricular rate was suggested by the similar long-term survival in a control group of consecutive patients receiving medical treatment for AF.
AVNA is usually proposed for elderly patients because it leads to pacemaker dependency. Patients with AVNA in our study were indeed markedly older than other AF patients. When this approach is under consideration, the patient has to be informed that this procedure results in a lifelong pacemaker dependency with potential complications. Sudden death secondary to torsades de pointes or ventricular fibrillation has been reported after AVNA. This outcome may be related to increased dispersion of ventricular refractoriness produced by sudden heart rate slowing and ventricular pacing. 28 However, we did not find a higher rate of death in the early phase after AVNA on event-free curves obtained in our propensitymatched analysis, AVNA has been advocated to ensure complete synchronized biventricular capture in AF patients treated with CRT. 16, 29, 30 AVNA in CRT-AF patients is often the only way to obtain 100% biventricular pacing and is associated with a 55% to 60% reduction in all-cause mortality and cardiovascular mortality and with improvement in mean functional class. 31 This has been recently confirmed with the results of the large CERTIFY registry in 7384 patients with CRT, among whom 443 had permanent AF and underwent AVNA. 15 In addition, AVNA in patients with implantable cardioverter defibrillator and CRT has the advantage of eradicating inappropriate shocks related to fast AF. By contrast, the need for CRT after AVNA has been debated. [32] [33] [34] According to recent guidelines, CRT post AVNA should be considered for those with reduced systolic function. 16 Pulmonary vein isolation may be superior to AVNA, with CRT in relatively young patients with heart failure with drug-refractory AF. 35 However, it should be stressed that the group of patients with CRT and AVNA in the PABA-CHF study (Pulmonary Vein Antrum Isolation vs AV Node Ablation With Biventricular Pacing for Treatment of Atrial Fibrillation in Patients With Congestive Heart Failure) was not a conventional population of HF patients because of their young age and moderately decreased left ventricular ejection fraction at enrollment. Our results suggest that AVNA can be offered as a safe alternative 
Limitations
Our results apply to patients included in the propensitymatching cohort and cannot be generalized for AF patients with lower risk than the ones included in the propensity score matching. Long-term clinical outcomes beyond pacemaker generator replacement are generally unknown because the mean follow-up duration of the study is 2.31 years. This registry-based study is observational and has the limitation of being a retrospective analysis. Among patients with AVNA, 88% had HF, and the rate of β-blocker use was 68%. This rate is, however, higher than that of previous studies in AF patients with HF 36 or in older randomized trials initially evaluating AVNA. 25, 26 Reliance on medical claims and a news-based website for mortality raises the concern that ascertainment of events may have been incomplete even if it would not be expected to introduce bias in any particular direction. Although adjustment was made for several variables, it is possible that residual confounders between the groups could have been omitted in the analysis, particularly those related to the severity of heart failure, possibly leading to CRT implantation. Propensity matching was not performed to analyze the effect of CRT in patients with AVNA because of insufficient statistical power. The results were similar after propensity matching or multivariate adjustment, but the observational method raises a question that some subgroups were merely managed better with subsequent treatment bias. Studies with long-term follow-up often risk unmeasurable effects of change in treatment over time. We were not able to determine whether patients with AVNA mainly had the procedure for palpitations, for heart failure, or for CRT optimization because these reasons may be interrelated. We did not analyze data on rehospitalization for cardiac events or heart failure. If a resident moved from the area and had new episodes of heart failure diagnosed elsewhere, information was unavailable to us. However, we see the ability to report nonrandomized, real-world registry data from a large cohort of consecutive patients as an advantage, not a weakness, because the data are complementary to the data reported in the few randomized clinical trials currently available. Observational studies such as this are of value because they reflect use of competing treatment options in current practice and because they include patients with a higher risk profile frequently not represented in clinical trials.
Conclusions
Limited randomized trial data have been published regarding AVNA in combination with conventional pacemaker therapy or CRT for AF. Large-scale randomized trials might still be needed to assess the efficacy of these therapies on hard clinical end points. 37 In sick AF patients with multiple comorbidities, AVNA with PVP, when used for rate control, was safe and may be associated with lower cardiovascular mortality during follow-up.
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